

# 1 Supplementary text

## 2 Supplementary Methods

### 3 Type 1: Bayesian Hierarchical linear regression for shedding dynamics

4 In order to model the decline in viral load over time, we set up a Bayesian model for the differences in Ct  
5 value for the two different cohorts. We included all participants of which the symptom onset date is  
6 known. We used a single phase model using following formula to estimate the response variable difference  
7 in Ct value (Y) over time since symptom onset (t) for each sample (s), as has been described previously (1).

$$8 \quad Y = \beta_s t + c_s$$

9 We assumed a prior distribution for each of our parameters. We placed a Gaussian prior on the intercept.  
10 The internal variation between samples are taken into account by assuming a normal distribution of the  
11 sample specific effect size.

$$12 \quad c \sim normal(0,1)$$

$$13 \quad \beta_s \sim normal(\beta, \sigma_\beta)$$

14 For the mean of the prior of the effect size, we placed a weakly informative Student T distribution as prior  
15 and assigned a half normal standard deviation.

$$16 \quad \beta \sim T(3, 0, 2.5)$$

$$17 \quad \sigma_\beta \sim half - normal(0, 1)$$

18 We assumed our response variable Y to be distributed according to a student-T distribution.

$$19 \quad Y \sim T(v_y, Y, \sigma_y)$$

20 We assumed priors of the parameters of this distribution:

21 
$$v \sim \text{exponential}\left(\frac{1}{30}\right)$$

22 
$$\sigma_y \sim \text{cauchy}(0, 5)$$

23 We used a normal distribution (mean =0 and variance = 0.5) for offset values for each distribution to train  
24 our models.

### 25 [Covariates and transformations](#)

26 We included the covariates sex, age, disease severity, weight class, baseline and day 42 antibody titer. Sex  
27 was defined as male or female. Age is split up in the categories child (under 18 years) and adults (18 years  
28 and above) at inclusion. Disease severity for SARS-CoV-2 infection is classified as severity score one to four,  
29 as described earlier (2, 3): (1) no symptoms related to respiratory infection, (2) mild symptoms  
30 (pharyngitis, rhinitis, mild dyspnea, mild or moderate coughing, gustatory dysfunction or olfactory  
31 dysfunction), (3) moderate symptoms (moderate or severe dyspnea, severe coughing, temperature > 38°C  
32 or a pneumonia diagnosed by a physician), and (4) hospital admission due to SARS-CoV-2-related  
33 symptoms. Weight class was defined as obese or not obese, based on BMI score. Antibody titers refer to  
34 SARS-CoV-2 Spike specific antigens tested at inclusion of study (baseline) and approximately 42 days after  
35 inclusion, which are categorized into (1) . Other covariates like number/type of vaccines, comorbidities,  
36 smoking habits and education level have been considered, but groups were too small to further investigate  
37 these.

38 All variables are transformed around the mean or categorized in order to fit the model.

### 39 [Type 2: Bayesian Hierarchical ANOVA model for minimum Ct value and for shedding duration](#)

40 A Bayesian Hierarchical ANOVA model was used to estimate the effect of covariates on the minimum Ct  
41 value of each participant. Each participant had up to possibly 10 saliva samples in an interval of 42 days,  
42 of which Ct values where determined. The lowest value out of these 10 samples is indicated as the  
43 minimum Ct value which corresponds with the peak of viral load.

44 A similar model was applied to the shedding duration, which is defined as the first day where a Ct value  
45 under 40 was measured, to the last day (i.e. the mean of two sequential sampling days) from symptom or  
46 shedding onset.

47 For both models we look at the effect size ( $\beta$ ), which is estimated for various covariates (X) as mentioned  
48 above to infer the correlation between these and minimum Ct value. The formula for this model is:

49 
$$Y = c_s + \sum_k \beta_{s,k} X_k$$

50 In this model, Y and its parameters follow the same distribution as explained before. In addition, we look  
51 at participant specific effect sizes of each variable in our model and assume a normal distribution of the  
52 sample specific effect size. Similar distributions apply to the priors in this model. Again, estimation of the  
53 effect size follows a normal distribution:

54 
$$\beta_{s,k} \sim normal(\beta_k, \sigma_{\beta_k})$$

55 The prior for  $\sigma_y$  has been narrowed for the duration model to the following:

56  
57 
$$\sigma_y \sim cauchy(0, 2)$$

58 And for the hierarchy in our model, we, again, assumed our response variable Y to be distributed according  
59 to a student-T distribution.

60 
$$Y \sim T(\nu_y, Y, \sigma_y)$$

61  
62  
63  
64

65 **Supplementary Table 1: Baseline tables.** Table shows baseline characteristics for both cohorts. Looking  
 66 at all individuals (a) and index cases only (b).

<b>Table 1a: Baseline characteristics all participants</b>			
<b>Characteristic</b>	<b>Overall, N = 343<sup>1</sup></b>	<b>Study</b>	
		<b>Sarsliva 1.0, N = 213<sup>1</sup></b>	<b>Sarsliva 2.0, N = 130<sup>1</sup></b>
<b>Sex</b>			
Male	166 (48%)	110 (52%)	56 (43%)
Female	177 (52%)	103 (48%)	74 (57%)
<b>Age, years</b>	34 (13-46)	30 (15-46)	36 (10-47)
<b>Child/adult</b>			
Adult (18 years and older)	217 (63%)	136 (64%)	81 (62%)
Child (under 18 years old)	126 (37%)	77 (36%)	49 (38%)
<b>Age group</b>			
0 to 11 years old	69 (20%)	33 (15%)	36 (28%)
12 to 17 years old	57 (17%)	44 (21%)	13 (10%)
18 to 39 years old	79 (23%)	55 (26%)	24 (18%)
40-49 years old	84 (24%)	47 (22%)	37 (28%)
50 years and older	54 (16%)	34 (16%)	20 (15%)
<b>Disease severity</b>			
Asymptomatic	62 (18%)	50 (23%)	12 (9.2%)
Mild symptoms	206 (60%)	122 (57%)	84 (65%)
Moderately severe symptoms	74 (22%)	40 (19%)	34 (26%)
Severe symptoms	1 (0.3%)	1 (0.5%)	0 (0%)
<b>Weight <sup>2</sup></b>			
Obesity	34 (9.9%)	17 (8.0%)	17 (13%)
No obesity	308 (90%)	195 (91%)	113 (86%)
Unknown	1	1	0
<b>Any comorbidities</b>	117 (34%)	61 (29%)	56 (43%)
<b>Atopy</b>	94 (28%)	47 (23%)	47 (36%)
Unknown	6	6	0
Cardiac comorbidities	4 (1.2%)	2 (0.9%)	2 (1.5%)
Pulmonary comorbidities	3 (0.9%)	2 (0.9%)	1 (0.8%)
Immunological comorbidities	4 (1.2%)	1 (0.5%)	3 (2.3%)
Diabetes Mellitus	4 (1.2%)	2 (0.9%)	2 (1.5%)
Rheumatologic comorbidities	2 (0.6%)	1 (0.5%)	1 (0.8%)
Other comorbidities	25 (7.3%)	14 (6.6%)	11 (8.5%)
<b>Smoking</b>	8 (2.3%)	5 (2.3%)	3 (2.3%)
<b>Immunity status</b>			
No immunity	235 (69%)	213 (100%)	22 (17%)
Previous infection	13 (3.8%)	0 (0%)	13 (10%)
Vaccination	83 (24%)	0 (0%)	83 (64%)
Hybrid immunity <sup>3</sup>	12 (3.5%)	0 (0%)	12 (9.2%)
<b>Antibody titer day 1</b>			
<10	10 (8.6%)	-	10 (8.6%)
10-100	2 (1.7%)	-	2 (1.7%)
100-1000	12 (10%)	-	12 (10%)
1000-10.000	66 (57%)	-	66 (57%)
>10.000	26 (22%)	-	26 (22%)

Unknown	227	213	14
<b>Antibody titer day 42</b>			
<10	14 (4.6%)	13 (6.8%)	1 (0.9%)
10-100	12 (3.9%)	12 (6.3%)	0 (0%)
100-1000	106 (35%)	96 (51%)	10 (8.7%)
1000-10.000	102 (33%)	69 (36%)	33 (29%)
>10.000	71 (23%)	0 (0%)	71 (62%)
Unknown	38	23	15
<b>Time from inclusion to last vaccination (days)</b>	88 (72-114)	-	88 (72-114)
Unknown	248	213	35
<b>Time from inclusion to last infection (days)</b>	115 (96-321)	-	115 (96-321)
Unknown	318	213	105
<b>Time from inclusion to last vaccination or exposure (days)</b>	89 (73-113)	-	89 (73-113)
Unknown	235	213	22
<sup>1</sup> n (%); Median (25%-75%)			
<sup>2</sup> BMI categories for index cases and household members <18 years of age were defined as BMI z-score (4); 2<, no obesity (underweight, normal weight, overweight); ≥2, obesity. BMI categories for index cases and household members ≥18 years of age were defined as <29.9 kg/m <sup>2</sup> , no obesity ; ≥30.0 kg/m <sup>2</sup> , obesity.			
<sup>3</sup> Previous infection and vaccination (at least 1 vaccination)			

67

Characteristic	Overall, N = 145 <sup>1</sup>	Study	
		Sarsliva 1.0, N = 79 <sup>1</sup>	Sarsliva 2.0, N = 54 <sup>1</sup>
<b>Sex</b>			
Male	44 (33%)	27 (34%)	17 (31%)
Female	89 (67%)	52 (66%)	37 (69%)
<b>Age, years</b>	39 (18-48)	39 (22-48)	38 (13-48)
<b>Child/adult</b>			
Adult (18 years and older)	100 (75%)	63 (80%)	37 (69%)
Child (under 18 years old)	33 (25%)	16 (20%)	17 (31%)
<b>Age group</b>			
0 to 11 years old	14 (11%)	1 (1.3%)	13 (24%)
12 to 17 years old	19 (14%)	15 (19%)	4 (7.4%)
18 to 39 years old	37 (28%)	25 (32%)	12 (22%)
40-49 years old	38 (29%)	22 (28%)	16 (30%)
50 years and older	25 (19%)	16 (20%)	9 (17%)
<b>Disease severity</b>			
Asymptomatic	5 (3.8%)	5 (6.3%)	0 (0%)
Mild symptoms	89 (67%)	52 (66%)	37 (69%)
Moderately severe symptoms	39 (29%)	22 (28%)	17 (31%)
<b>Weight<sup>2</sup></b>			
Obesity	15 (11%)	8 (10%)	7 (13%)
No obesity	130 (90%)	71 (90%)	47 (87%)
<b>Any comorbidities</b>	50 (38%)	26 (33%)	24 (44%)
<b>Atopy</b>	41 (31%)	20 (25%)	21 (39%)

<b>Cardiac comorbidities</b>	3 (2.3%)	2 (2.5%)	1 (1.9%)
<b>Pulmonary comorbidities</b>	1 (0.8%)	1 (1.3%)	0 (0%)
<b>Immunological comorbidities</b>	2 (1.5%)	1 (1.3%)	1 (1.9%)
<b>Diabetes Mellitus</b>	1 (0.8%)	0 (0%)	1 (1.9%)
<b>Rheumatologic comorbidities</b>	0 (0%)	0 (0%)	0 (0%)
<b>Other comorbidities</b>	5 (3.8%)	3 (3.8%)	2 (3.7%)
<b>Smoking</b>	5 (3.8%)	3 (3.8%)	2 (3.7%)
<b>Immunity status</b>			
No immunity	86 (65%)	79 (100%)	7 (13%)
Previous infection	5 (3.8%)	0 (0%)	5 (9.3%)
Vaccination	38 (29%)	0 (0%)	38 (70%)
Hybrid immunity <sup>3</sup>	4 (3.0%)	0 (0%)	4 (7.4%)
<b>Antibody titer day 1</b>			
<b>&lt;10</b>	3 (6.0%)	-	3 (6.0%)
<b>10-100</b>	0 (0%)	-	0 (0%)
<b>100-1000</b>	5 (10%)	-	5 (10%)
<b>1000-10.000</b>	30 (60%)	-	30 (60%)
<b>&gt;10.000</b>	12 (24%)	-	12 (24%)
Unknown	83	79	4
<b>Antibody titer day 42</b>			
<b>&lt;10</b>	5 (4.0%)	4 (5.4%)	1 (2.0%)
<b>10-100</b>	2 (1.6%)	2 (2.7%)	0 (0%)
<b>100-1000</b>	45 (36%)	43 (58%)	2 (4.0%)
<b>1000-10.000</b>	39 (31%)	25 (34%)	14 (28%)
<b>&gt;10.000</b>	33 (27%)	0 (0%)	33 (66%)
Unknown	9	5	4
<b>Time from inclusion to last vaccination (days)</b>	89 (74-115)	-	89 (74-115)
Unknown	91	79	12
<b>Time from inclusion to last infection (days)</b>	118 (96-276)	-	118 (96-276)
Unknown	124	79	45
<b>Time from inclusion to last vaccination or exposure (days)</b>	90 (76-116)	-	90 (76-116)
Unknown	86	79	7
<b>Time from symptom onset to GGD-test (days)</b>	1 (1-2)	1 (1-2)	1 (1-2)
<b>Time GGD-test to saliva day 1 (days)</b>	3 (2-4)	4 (3-4)	1 (1-2)
<b>Time symptom onset tot inclusion (days)</b>	4 (3-5)	5 (4-5)	3 (2-4)
<sup>1</sup> n (%); Median (25%-75%)			
<sup>2</sup> BMI categories for index cases and household members <18 years of age were defined as BMI z-score (4); 2<, no obesity (underweight, normal weight, overweight); ≥2, obesity. BMI categories for index cases and household members ≥18 years of age were defined as <29.9 kg/m <sup>2</sup> , no obesity ; ≥30.0 kg/m <sup>2</sup> , obesity.			
<sup>3</sup> Previous infection and vaccination (at least 1 vaccination)			

68

69

70 **Supplementary Table 2. Model setup and outcome.** Table indicates the different types of model, using  
71 various input values. We made a division between the cohorts and indicated covariates of each model.  
72 The effects of the models are indicated in the last column. A non-trivial effect has a 95%-credibility interval  
73 that does not include 0. Significant effects are indicated in bold.

Model description	cohort	Number of input samples	Main variable	covariates	Posterior distribution median (CI 95% lower – upper)				
<b>Type 1: shedding decay model</b>	SL1	2131	Ct value for day since onset						
	SL2	1300	Ct value for day since onset						
<b>Type 2: ANOVA for minimum Ct value</b>	SL1	213	Minimum Ct value per participant	Sex	-0.06 (-0.19 – 0.07)				
				age category (child/adult)	-0.15 (-0.30 – 0.00)				
				weight class (obesity/ no obesity)	-0.18 (-0.52 – 0.14)				
				disease severity (category 1 – 4)	<b>0.14 (0.03 – 0.24)</b>				
				transformed SARS-CoV-2 specific antibody titer at day 42	<b>0.11 (0.03 – 0.20)</b>				
	SL2	130	Minimum Ct value per participant	Sex	-0.04 (-0.21 – 0.13)				
				age category (child/adult)	<b>-0.31 (-0.55 – -0.06)</b>				
				weight class (obesity/ no obesity)	0.03 (-0.16 – 0.23)				
				disease severity (category 1 – 4)	0.01 (-0.14 – 0.15)				
				transformed SARS-CoV-2 specific antibody titer at baseline	<b>-0.13 (-0.26 – 0.00)</b>				
				transformed SARS-CoV-2 specific antibody titer at day 42	<b>0.18 (0.01 – 0.34)</b>				
				<b>Type 3: ANOVA for shedding duration</b>	SL1	210	Duration of shedding per participant	Sex	<b>0.01 (0.00 – 0.02)</b>
								age category (child/adult)	-0.00 (-0.01- 0.01)
								weight class (obesity/ no obesity)	-0.00 (-0.02 – 0.02)
								disease severity (category 1 – 4)	<b>0.01 (0.00 – 0.02)</b>
transformed SARS-CoV-2 specific antibody titer at day 42	<b>0.01 (0.01 – 0.02)</b>								
	SL2	130	Duration of shedding per participant	Sex	-0.00 (-0.01 – 0.00)				
				age category (child/adult)	<b>-0.02 (-0.03 - -0.01)</b>				
				weight class (obesity/ no obesity)	0.00 (-0.01 - 0.01)				
				disease severity (category 1 – 4)	0.00 (-0.00 – 0.01)				
				transformed SARS-CoV-2 specific antibody titer at baseline	<b>-0.01 (-0.02 – -0.00)</b>				

				transformed SARS-CoV-2 specific antibody titer at day 42	0.00 (-0.00 – 0.01)
Abbreviations: CI (credibility interval)					

74

75

76 [Supplemental references](#)

77 1. van Gils MJ, van Willigen HDG, Wynberg E, Han AX, van der Straten K, Burger JA, et al. A single  
78 mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants  
79 of concern. *Cell Rep Med.* 2022;3(1):100486.

80 2. Winkel A, Kozañli E, Haverkort M, Euser S, Sluiter-Post J, Mariman R, et al. Lower levels of  
81 household transmission of SARS-CoV-2 VOC Omicron compared to Wild-type: an interplay between  
82 transmissibility and immune status. *medRxiv.* 2024.

83 3. Kolodziej LM, van Lelyveld SFL, Haverkort ME, Mariman R, Sluiter-Post JGC, Badoux P, et al. High  
84 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission Rates Detected  
85 by Dense Saliva Sampling. *Clin Infect Dis.* 2022;75(1):e10-e9.

86 4. Centers for Disease C, Prevention. Z-score Data Files.

87